Try now!
27.
09.15
10:10

New results show tumor-targeting activity of KEYTRUDA (Pembrolizumab) in patients with advanced nasopharyngeal carcinoma

Source
FinanzNachrichten.de
Stay up to date!
Subscribe to our free newsletter

Our weekly newsletter is published every Monday and summarizes the most important changes in the agricultural markets. Focal points are presented graphically.

By registration you accept the terms and conditions and the privacy policy.
You can unsubscribe from our newsletter at any time.

+49 228 22722110

Mon-Fri 8-12 o'clock

Contact
Callback service 

Get it on Google Play
Download on the App Store

Not found what you're looking for?

Content type
Rückrufservice
Please describe your request so that we can prepare for the callback.
Yes, I have read the Privacy Policy note and I consent that the data provided by me, including the contact data, for the processing of the inquiry and in case of questions are electronically collected and stored. My data will only be used strictly for my request and will not be passed without my consent. This consent can be revoked any time with effect for the future.'
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Help?

Do you have questions about ZMP Live? Our team will be happy to help you. Please feel free to send us a message:

Our privacy policy applies

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Register now

Jetzt registrieren und ZMP Live+ 14 Tage kostenlos testen!
  • Dauerhaft kostenfrei
  • Keine Zahlungsinformationen erforderlich
No, thanks!